Skip to ContentSkip to Navigation
Over ons Praktische zaken Waar vindt u ons dr. L.A. (Lisa) de Jong

Speerpunten

Lisa heeft een achtergrond in de farmacie en heeft haar promotieonderzoek 'Gezondheidseconomie van directe orale anticoagulantia in Nederland' uitgevoerd bij de afdeling Farmacotherapie, -epidemiologie en -economie van de Rijksuniversiteit Groningen. Haar onderzoek richt zich op gezondheidseconomische modellering voor vergoedings- en klinische besluitvormingsdoeleinden, met speciale interesse in het gebruik van real-world data en expertise op het gebied van cardiorenale en cardiometabole ziekten. Momenteel is Lisa als gezondheidsecononoom betrokken bij verschillende onderzoeksprojecten en 'technical appraisals' voor het National Institute for Health and Care Excellence in het Verenigd Koninkrijk. Expertise: farmaco-economie, gezondheidseconomie, ziektelast, budgetimpact, health technology assessment, kosteneffectiviteit.

Publicaties

A Systematic Review of Health-Related Quality of Life in Women with HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab

Differences in evidentiary requirements for oncology drug effectiveness assessments among six European health technology assessment bodies: can alignment be improved?

Budget and health impact of switching eligible patients with atrial fibrillation to lower- dose dabigatran

Cost-effectiveness model of trastuzumab deruxtecan as second-line treatment in HER2-positive unresectable and/or metastatic breast cancer in Finland

Cost-Effectiveness Models of Continuous Glucose Monitoring in Individuals With Type 1 Diabetes: A Systematic Review on Methodology and Quality

Cost-effectiveness of ravulizumab compared with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria in the Netherlands

Facing problems in radiotherapy for breast cancer patients in Yogyakarta, Indonesia: A cohort retrospective study

Model and Empirical Data-Based Cost-Utility Studies of Continuous Glucose Monitoring in Individuals with Type 1 Diabetes: A Protocol of a Systematic Review on Methodology and Quality

The Use of eHealth for Pharmacotherapy Management With Patients With Respiratory Disease, Cardiovascular Disease, or Diabetes: Scoping Review

Correction: Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings

Lees meer